CTI BioPharma Corp.
(NASDAQ CM: CTIC)
Rigrodsky Law, P.A. is investigating CTI BioPharma Corp. (“CTI”) regarding possible breaches of fiduciary duties and other violations of law related to CTI’s agreement to be acquired by Swedish Orphan Biovitrum AB. Under the terms of the agreement, CTI shareholders will receive $9.10 per share in cash.